

 



<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:foaf="http://xmlns.com/foaf/0.1/"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
      xmlns:xsd="http://www.w3.org/2001/XMLSchema-datatypes#"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">
<head prefix="og: http://ogp.me/ns#">
  <title>PLOS ONE: Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure</title>


<link rel="stylesheet" type="text/css"  href="/css/global-min.css?v=izteQ6tu7kgsJZW_xmrYizvKiHM" />


    <!--[if lte IE 7]>
<link rel="stylesheet" type="text/css"  href="/css/lte_ie7-min.css?v=3bykQUyQmReeuobVyPozcJ9LxRc" />
    <![endif]-->


<link rel="stylesheet" type="text/css"  href="/css/jquery-ui-min.css?v=eXDHTEJM0lIAmDe5k0I0Ad4nxNo" />


<link rel="stylesheet" type="text/css"  href="/css/journal.css?v=T7ZVxJfgk9jNxLAJ2qHz1vZpgYU" />


<link rel="stylesheet" type="text/css" media="print" href="/css/print-min.css?v=T5lb0B3q6EXBsuDluc5V5w+AkRc" />


  <link rel="stylesheet" href="http://f.fontdeck.com/s/css/js/www.plosone.org/24557.css" type="text/css"/>

  <!--chartbeat -->
  <script type="text/javascript">var _sf_startpt = (new Date()).getTime()</script>
  <script>document.documentElement.className += ' js';</script>

  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7; IE=EmulateIE9"/>
  <meta name="description" content="PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world."/>
  <meta name="keywords" content="PLOS, Public Library of Science, Open Access, Open-Access, Science, Medicine, Biology, Research, Peer-review, Inclusive, Interdisciplinary, Ante-disciplinary, Physics, Chemistry, Engineering"/>
  <meta name="almHost" content="http://alm.plos.org/api/v3/articles"/>
  <meta name="searchHost" content="http://api.plos.org/search" />
  <meta name="termsHost" content="http://api.plos.org/terms" />
  <meta name="solrApiKey" content="plos"/>
  <meta name="almAPIKey" content="3pezRBRXdyzYW6ztfwft" />
  <meta name="currentJournal" content="PLoSONE" />
  <meta name="almRequestBatchSize" content="" />

  <meta name="citation_publisher" content="Public Library of Science"/>
  <meta name="citation_doi" content="10.1371/journal.pone.0000941"/>
  <meta name="dc.identifier" content="10.1371/journal.pone.0000941" />

    <meta name="citation_title" content="Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure"/>
    <meta itemprop="name" content="Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure"/>

      <meta name="citation_author" content="Biju Parekkadan"/>
            <meta name="citation_author_institution" content="Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, Massachusetts, United States of America"/>
      <meta name="citation_author" content="Daan van Poll"/>
            <meta name="citation_author_institution" content="Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Department of Surgery, University Medical Center, University of Utrecht, Utrecht, The Netherlands"/>
      <meta name="citation_author" content="Kazuhiro Suganuma"/>
            <meta name="citation_author_institution" content="Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America"/>
      <meta name="citation_author" content="Edward A. Carter"/>
            <meta name="citation_author_institution" content="Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America"/>
      <meta name="citation_author" content="François Berthiaume"/>
            <meta name="citation_author_institution" content="Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America"/>
      <meta name="citation_author" content="Arno W. Tilles"/>
            <meta name="citation_author_institution" content="Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America"/>
      <meta name="citation_author" content="Martin L. Yarmush"/>
            <meta name="citation_author_institution" content="Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America"/>
            <meta name="citation_author_institution" content="Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, Massachusetts, United States of America"/>

    <meta name="citation_date" content="2007/9/26"/>

  <meta name="citation_pdf_url" content="http://dx.plos.org/10.1371/journal.pone.0000941.pdf" />

      <meta name="citation_journal_title" content="PLOS ONE" />
    <meta name="citation_firstpage" content="e941"/>
    <meta name="citation_issue" content="9"/>
    <meta name="citation_volume" content="2"/>
    <meta name="citation_issn" content="1932-6203"/>

    <meta name="citation_journal_abbrev" content="PLoS ONE" />

      <meta name="citation_reference" content="citation_title=A bioartificial liver–state of the art.; citation_author=AJ Strain; citation_author=JM Neuberger; citation_journal_title=Science; citation_volume=295; citation_number=1; citation_pages=1005-1009; citation_date=2002; " />
      <meta name="citation_reference" content="citation_title=A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats.; citation_author=M Shinoda; citation_author=AW Tilles; citation_author=N Kobayashi; citation_author=G Wakabayashi; citation_author=A Takayanagi; citation_journal_title=J Surg Res; citation_volume=137; citation_number=2; citation_pages=130-140; citation_date=2007; " />
      <meta name="citation_reference" content="citation_title=Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist.; citation_author=M Shinoda; citation_author=AW Tilles; citation_author=G Wakabayashi; citation_author=A Takayanagi; citation_author=H Harada; citation_journal_title=Tissue Eng; citation_volume=12; citation_number=3; citation_pages=1313-1323; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=The role of mesenchymal stem cells in haemopoiesis.; citation_author=F Dazzi; citation_author=R Ramasamy; citation_author=S Glennie; citation_author=SP Jones; citation_author=I Roberts; citation_journal_title=Blood Rev; citation_volume=20; citation_number=4; citation_pages=161-171; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep.; citation_author=KW Liechty; citation_author=TC MacKenzie; citation_author=AF Shaaban; citation_author=A Radu; citation_author=AM Moseley; citation_journal_title=Nat Med; citation_volume=6; citation_number=5; citation_pages=1282-1286; citation_date=2000; " />
      <meta name="citation_reference" content="citation_title=Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.; citation_author=K Le Blanc; citation_author=I Rasmusson; citation_author=B Sundberg; citation_author=C Gotherstrom; citation_author=M Hassan; citation_journal_title=Lancet; citation_volume=363; citation_number=6; citation_pages=1439-1441; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Human mesenchymal stem cells modulate allogeneic immune cell responses.; citation_author=S Aggarwal; citation_author=MF Pittenger; citation_journal_title=Blood; citation_volume=105; citation_number=7; citation_pages=1815-1822; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Simultaneous injection of bone marrow cells and stromal cells into bone marrow accelerates hematopoiesis in vivo.; citation_author=Y Zhang; citation_author=Y Adachi; citation_author=Y Suzuki; citation_author=K Minamino; citation_author=M Iwasaki; citation_journal_title=Stem Cells; citation_volume=22; citation_number=8; citation_pages=1256-1262; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.; citation_author=R Meisel; citation_author=A Zibert; citation_author=M Laryea; citation_author=U Gobel; citation_author=W Daubener; citation_journal_title=Blood; citation_volume=103; citation_number=9; citation_pages=4619-4621; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.; citation_author=S Beyth; citation_author=Z Borovsky; citation_author=D Mevorach; citation_author=M Liebergall; citation_author=Z Gazit; citation_journal_title=Blood; citation_volume=105; citation_number=10; citation_pages=2214-2219; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation.; citation_author=B Maitra; citation_author=E Szekely; citation_author=K Gjini; citation_author=MJ Laughlin; citation_author=J Dennis; citation_journal_title=Bone Marrow Transplant; citation_volume=33; citation_number=11; citation_pages=597-604; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells.; citation_author=M Gnecchi; citation_author=H He; citation_author=OD Liang; citation_author=LG Melo; citation_author=F Morello; citation_journal_title=Nat Med; citation_volume=11; citation_number=12; citation_pages=367-368; citation_date=2005; " />
      <meta name="citation_reference" content="citation_title=Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement.; citation_author=M Gnecchi; citation_author=H He; citation_author=N Noiseux; citation_author=OD Liang; citation_author=L Zhang; citation_journal_title=Faseb J; citation_volume=20; citation_number=13; citation_pages=661-669; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=A fulminant hepatic failure model in the rat: involvement of interleukin-1beta and tumor necrosis factor-alpha.; citation_author=M Shito; citation_author=UJ Balis; citation_author=RG Tompkins; citation_author=ML Yarmush; citation_author=M Toner; citation_journal_title=Dig Dis Sci; citation_volume=46; citation_number=14; citation_pages=1700-1708; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Immunomodulation of Activated Hepatic Stellate Cells by Mesenchymal Stem Cells.; citation_author=B Parekkadan; citation_author=D van Poll; citation_author=Z Megeed; citation_author=AW Tilles; citation_author=F Berthiaume; citation_journal_title=Biochem Biophys Res Commun.; citation_number=15; citation_date=2007; " />

  <link rel="canonical" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000941" />

    <meta name="twitter:card" content="summary"/>
    <meta name="twitter:site" content="@plosone"/>
    <meta name="twitter:title" content="Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure"/>
    <meta name="twitter:description" content="Modulation of the immune system may be a viable alternative in the treatment of fulminant hepatic failure (FHF) and can potentially eliminate the need for donor hepatocytes for cellular therapies. Multipotent bone marrow-derived mesenchymal stem cells (MSCs) have been shown to inhibit the function of various immune cells by undefined paracrine mediators in vitro. Yet, the therapeutic potential of MSC-derived molecules has not been tested in immunological conditions in vivo. Herein, we report that the administration of MSC-derived molecules in two clinically relevant forms-intravenous bolus of conditioned medium (MSC-CM) or extracorporeal perfusion with a bioreactor containing MSCs (MSC-EB)-can provide a significant survival benefit in rats undergoing FHF. We observed a cell mass-dependent reduction in mortality that was abolished at high cell numbers indicating a therapeutic window. Histopathological analysis of liver tissue after MSC-CM treatment showed dramatic reduction of panlobular leukocytic infiltrates, hepatocellular death and bile duct duplication. Furthermore, we demonstrate using computed tomography of adoptively transferred leukocytes that MSC-CM functionally diverts immune cells from the injured organ indicating that altered leukocyte migration by MSC-CM therapy may account for the absence of immune cells in liver tissue. Preliminary analysis of the MSC secretome using a protein array screen revealed a large fraction of chemotactic cytokines, or chemokines. When MSC-CM was fractionated based on heparin binding affinity, a known ligand for all chemokines, only the heparin-bound eluent reversed FHF indicating that the active components of MSC-CM reside in this fraction. These data provide the first experimental evidence of the medicinal use of MSC-derived molecules in the treatment of an inflammatory condition and support the role of chemokines and altered leukocyte migration as a novel therapeutic modality for FHF."/>
      <meta name="twitter:image" content="http://dx.plos.org/10.1371/journal.pone.0000941.g006"/>

  <meta property="og:title" content="Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure" />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0000941" />

 <!--end articleInfoX-->

  <link rel="pingback" href="http://www.plosone.org/pingback" />


  <link rel="shortcut icon" href="/images/favicon.ico" type="image/x-icon"/>
  <link rel="home" title="home" href="/"/>
  <link rel="alternate" type="application/rss+xml"
        title="PLOS ONE: New Articles"
        href="http://www.plosone.org/article/feed"/>
</head>
<body>

  <div id="page-wrap">
    <div id="topbanner" class="cf">

<!-- Div for the ad at the top of journal home page-->
<div class="center">
  <div class="title">Advertisement</div>
  <iframe id='a3ac9da4' name='a3ac9da4'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=345&amp;cb=7421'
    frameborder='0' scrolling='no' width='730' height='90'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a3ac9da4&amp;cb=8313'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=345&amp;cb=3284&amp;n=a3ac9da4'
      border='0' alt=''/>
    </a>
  </iframe>
</div>    </div>

    <div id="pagehdr-wrap">
      <div id="pagehdr">
        <div id="user" class="nav">
          <ul>
            <li><a href="http://www.plos.org">plos.org</a></li>
            <li><a href="https://register.plos.org/ambra-registration/register.action">create account</a></li>
            <li class="btn-style"><a
              href="/user/secure/secureRedirect.action?goTo=%2Farticle%2FfetchArticle.action%3FarticleURI%3Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0000941">sign in</a>
            </li>
          </ul>
        </div>
        <div class="logo">
          <a href="/"><img src="/images/logo.png" alt="PLOS ONE"></a>
        </div>

<div id="nav-main" class="nav">
  <ul>
        <li id="mn-01"><a href="/taxonomy" class="areas-link">Subject Areas</a></li>
    <li id="mn-02"><a href="javascript:void(0);">For Authors</a>
      <div class="submenu" style="width: 540px; margin-left: -300px;">
        <div class="block">
          <div class="submit-script">
            <h3>Submit your Manuscript</h3>
            <ul>
              <li>Fair, rigorous peer review</li>
              <li>Broad scope and wide reach</li>
            </ul>
            <a href="/static/submissionInstructions" class="btn">get started</a>
          </div>
        </div>
        <div class="menu">
          <ul>
            <li><a href="/static/publish">Why Publish with PLOS ONE</a></li>
            <li><a href="/static/publication">Publication Criteria</a></li>
            <li><a href="/static/editorial">Editorial Policies</a></li>
            <li><a href="/static/guidelines">Preparing A Manuscript</a></li>
            <li><a href="/static/figureGuidelines">Figure and Table Guidelines</a></li>
          <li><a href="/static/supportingInformation">Supporting Information Guidelines</a></li>
            <li><a href="/static/submissionInstructions">Submitting a Manuscript</a></li>
          </ul>
        </div>
      </div>
    </li>

    <li id="mn-03"><a href="javascript:void(0);">About Us</a>
      <div class="submenu" style="width:248px; margin-left:-30px;">
        <div class="menu">
          <ul>
            <li><a href="/static/information">Journal Information</a></li>
            <li><a href="/static/edboard">Editorial Board</a></li>
            <li><a href="/static/reviewerGuidelines">Reviewer Guidelines</a></li>
            <li><a href="/static/almInfo">Article-Level Metrics</a></li>
            <li><a href="/static/license">Open-Access License</a></li>
            <li><a href="/static/downloads">Media Downloads</a></li>
            <li><a href="/static/commentGuidelines">Guidelines for Comments</a></li>
            <li><a href="/static/corrections">Corrections</a></li>
            <li><a href="/static/help">Help Using this Site</a></li>
            <li><a href="/static/contact">Contact Us</a></li>
          </ul>
        </div>
      </div>
    </li>
  </ul>
<div id="db">
  <form name="searchForm" action="/search/simple?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000941" method="get" >
<input type="hidden" name="from" value="globalSimpleSearch" id="from"/><input type="hidden" name="filterJournals" value="PLoSONE" id="filterJournals"/>    <fieldset>
      <legend>Search</legend>
      <label for="search">Search</label>
      <div class="wrap">
        <input id="search" type="text" name="query" placeholder="Search">
        <input type="image" alt="SEARCH" src="/images/icon.search.gif">
      </div>
    </fieldset>
  </form>
    <a id="advSearch" href="/search/advanced?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000941&filterJournals=PLoSONE">advanced search</a>
</div></div>

      </div>
      <!-- pagehdr-->
    </div>
    <!-- pagehdr-wrap -->

  <!--body and html tags gets closed in global_footer.ftl-->
<script type="text/javascript" src="/javascript/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>

<div id="pagebdy-wrap">
  <div id="pagebdy">

    <div id="article-block" class="cf">

<div class="article-meta cf">
  <ul id="almSignPost" style="display: none;"></ul>
  <div class="article-type">
    <span class="type oa">Open Access</span>
      <span class="type pr">Peer-Reviewed</span>
  </div>
</div>

<div class="header" id="hdr-article">

<div class="article-kicker">
      <span id="article-type-heading">
        Research Article
      </span>
</div>  <h1 property="dc:title" datatype="" rel="dc:type" href="http://purl.org/dc/dcmitype/Text">
    Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure
  </h1>

  <ul class="authors">
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Biju Parekkadan
              <span class="equal-contrib"
                    title="These authors contributed equally to this work">equal contributor</span>, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">

                <p><span class="equal-contrib" title="These authors contributed equally to this work">equal contributor</span>
                Contributed equally to this work with: Biju Parekkadan, Daan van Poll, Kazuhiro Suganuma</p>

              
              

                <p>Affiliations:
                  Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America, 
                  Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Daan van Poll
              <span class="equal-contrib"
                    title="These authors contributed equally to this work">equal contributor</span>, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">

                <p><span class="equal-contrib" title="These authors contributed equally to this work">equal contributor</span>
                Contributed equally to this work with: Biju Parekkadan, Daan van Poll, Kazuhiro Suganuma</p>

              
              

                <p>Affiliations:
                  Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America, 
                  Department of Surgery, University Medical Center, University of Utrecht, Utrecht, The Netherlands
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Kazuhiro Suganuma
              <span class="equal-contrib"
                    title="These authors contributed equally to this work">equal contributor</span>, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">

                <p><span class="equal-contrib" title="These authors contributed equally to this work">equal contributor</span>
                Contributed equally to this work with: Biju Parekkadan, Daan van Poll, Kazuhiro Suganuma</p>

              
              

                <p>Affiliation:
                  Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Edward A. Carter, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            François Berthiaume, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Arno W. Tilles, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Martin L. Yarmush
              <span class="corresponding">mail</span>
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              <p><span class="email">*</span>To whom correspondence should be addressed. E-mail: <a href="mailto:ireis@sbi.org">ireis@sbi.org</a></p>

                <p>Affiliations:
                  Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and the Shriners Hospitals for Children, Boston, Massachusetts, United States of America, 
                  Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, Massachusetts, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
  </ul>
  <ul class="date-doi-line">
    <li>Published: September 26, 2007</li>
    <li>DOI: 10.1371/journal.pone.0000941</li>
  </ul>


</div><!--end header-->
<div class="main cf" id="pjax-container">
  

<div class="nav items-5" id="nav-article">
  <ul>
  <li>
        <span class="active" name="article">Article</span>
  </li>
  <li>
      <a href="/article/authors/info%3Adoi%2F10.1371%2Fjournal.pone.0000941" name="authors">About the Authors</a>
  </li>
  <li>
      <a href="/article/metrics/info%3Adoi%2F10.1371%2Fjournal.pone.0000941" name="metrics">Metrics</a>
  </li>
  <li>
      <a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000941" name="comments">Comments</a>
  </li>
  <li>
      <a href="/article/related/info%3Adoi%2F10.1371%2Fjournal.pone.0000941" name="related">Related Content</a>
  </li>
  </ul>
</div>

<script type="text/javascript">
  var selected_tab = "article";
</script>
  <div id="figure-thmbs" class="carousel cf">
    <div class="wrapper">
      <div class="slider">
              <div class="item">
                <a href="#pone-0000941-g001" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g001" title="Figure 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000941-g002" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g002" title="Figure 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000941-g003" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g003" title="Figure 3">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g003&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000941-g004" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g004" title="Figure 4">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g004&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000941-g005" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g005" title="Figure 5">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g005&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0000941-g006" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g006" title="Figure 6">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g006&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
      </div>
    </div>
  </div>

  <div class="nav-col">
    <div class="nav" id="nav-article-page">
      <ul>
        <li class="nav-col-comments"><a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0000941">Reader Comments (2)</a></li>
          <li id="nav-figures"><a data-doi="info:doi/10.1371/journal.pone.0000941" >Figures</a></li>
      </ul>
    </div>
  </div>

  <div class="article">







<div class="abstract"><a id="abstract0" name="abstract0" toc="abstract0" title="Abstract"></a><h2>Abstract</h2><a id="article1.front1.article-meta1.abstract1.p1" name="article1.front1.article-meta1.abstract1.p1"></a><p>Modulation of the immune system may be a viable alternative in the treatment of fulminant hepatic failure (FHF) and can potentially eliminate the need for donor hepatocytes for cellular therapies. Multipotent bone marrow-derived mesenchymal stem cells (MSCs) have been shown to inhibit the function of various immune cells by undefined paracrine mediators <em>in vitro</em>. Yet, the therapeutic potential of MSC-derived molecules has not been tested in immunological conditions <em>in vivo.</em> Herein, we report that the administration of MSC-derived molecules in two clinically relevant forms-intravenous bolus of conditioned medium (MSC-CM) or extracorporeal perfusion with a bioreactor containing MSCs (MSC-EB)-can provide a significant survival benefit in rats undergoing FHF. We observed a cell mass-dependent reduction in mortality that was abolished at high cell numbers indicating a therapeutic window. Histopathological analysis of liver tissue after MSC-CM treatment showed dramatic reduction of panlobular leukocytic infiltrates, hepatocellular death and bile duct duplication. Furthermore, we demonstrate using computed tomography of adoptively transferred leukocytes that MSC-CM functionally diverts immune cells from the injured organ indicating that altered leukocyte migration by MSC-CM therapy may account for the absence of immune cells in liver tissue. Preliminary analysis of the MSC secretome using a protein array screen revealed a large fraction of chemotactic cytokines, or chemokines. When MSC-CM was fractionated based on heparin binding affinity, a known ligand for all chemokines, only the heparin-bound eluent reversed FHF indicating that the active components of MSC-CM reside in this fraction. These data provide the first experimental evidence of the medicinal use of MSC-derived molecules in the treatment of an inflammatory condition and support the role of chemokines and altered leukocyte migration as a novel therapeutic modality for FHF.</p>
</div>


<div class="articleinfo"><p><strong>Citation: </strong>Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, et al.  (2007) Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure. PLoS ONE 2(9):
          e941.
            doi:10.1371/journal.pone.0000941</p><p><strong>Academic Editor: </strong>Fu-Sheng Wang, Beijing Institute of Infectious Diseases, China</p><p><strong>Received:</strong> June 9, 2007; <strong>Accepted:</strong> September 7, 2007; <strong>Published:</strong> September 26, 2007</p><p><strong>Copyright:</strong> © 2007 Parekkadan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Funding: </strong>BP was supported by a National Science Foundation predoctoral fellowship. DVP was supported by a fellowship from the Michael van Vlooten foundation. This work was partially supported by grants from the National Institutes of Health (K08 DK66040, K18 DK076819 and R01 DK43371) and the Shriners Hospitals for Children.</p><p><strong>Competing interests:</strong> The authors have declared that no competing interests exist.</p></div>





<div id="section1" class="section"><a id="s1" name="s1" toc="s1" title="Introduction"></a><h3>Introduction</h3><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1"></a><p>Clinical trials testing the efficacy of bioartificial liver support in treating fulminant hepatic failure (FHF) have provided some promising results, yet the current generation of devices has not demonstrated sufficient efficacy and reliability for routine use, primarily due to a lack of a functionally stable, human hepatocyte source <a href="#pone.0000941-Strain1">[1]</a>. We have previously shown that immunomodulation via interleukin-1 receptor antagonism in the form of: (a) the recombinant protein, (b) adenoviral vector gene therapy, or (c) transfected hepatocytes seeded in an extracorporeal device, can provide a survival benefit in an animal model of FHF <a href="#pone.0000941-Shinoda1">[2]</a>, <a href="#pone.0000941-Shinoda2">[3]</a>. However, due to concerns associated with gene transfer <em>in vivo</em> or <em>ex vivo</em> and the expense of recombinant protein production, we sought to identify a natural human “cellular equivalent” of immunomodulation that could be incorporated into bioartificial liver assist devices.</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2"></a><p>Within the bone marrow space multipotent stromal cells, also referred to as mesenchymal stem cells (MSCs), are known to be the precursor cell for stromal tissues that support hematopoiesis <a href="#pone.0000941-Dazzi1">[4]</a>. The immunomodulatory function of MSCs was first reported after it was observed that they could evade immunosurveillance after cell transplantation <a href="#pone.0000941-Liechty1">[5]</a>. This ability of MSCs to alter an immune response has been exploited for therapeutic purposes as demonstrated by the case of a patient suffering from steroid-refractory graft-versus-host disease who was successfully treated by the infusion of haploidentical MSCs <a href="#pone.0000941-LeBlanc1">[6]</a>. I<em>n vitro</em> studies have subsequently shown that MSCs actively inhibit the function of several immune cells through secreted cytokines, growth factors and enzymatic action, although controversy exists on the identity of the responsible mediators <a href="#pone.0000941-Aggarwal1">[7]</a>, <a href="#pone.0000941-Zhang1">[8]</a>, <a href="#pone.0000941-Meisel1">[9]</a>, <a href="#pone.0000941-Beyth1">[10]</a>, <a href="#pone.0000941-Maitra1">[11]</a>. The fortification of the soluble microenvironment by MSCs can also affect non-hematopoietic cells as well. MSCs used for cellular cardiomyoplasty after an ischemic event revealed that MSC-derived soluble molecules inhibited hypoxia-induced apoptosis of cardiomyocytes during the acute phase of injury resolution <a href="#pone.0000941-Gnecchi1">[12]</a>, <a href="#pone.0000941-Gnecchi2">[13]</a>. Taken together, these studies indicate that MSCs can independently affect immune and tissue cells by paracrine means.</p>
<a id="article1.body1.sec1.p3" name="article1.body1.sec1.p3"></a><p>On this basis, we hypothesized that the paracrine function of MSCs may be of therapeutic value when used in the setting of acute organ failure, wherein parenchymal cell loss is integrated with a local and systemic inflammatory response. Here, we report a significant survival benefit in the treatment of FHF after intravenous delivery of MSC biomolecules in the form of bolus injections of conditioned medium (MSC-CM) or a MSC-based extracorporeal bioreactor (MSC-EB). The survival benefit of MSC-CM was a function of the cell mass used for media conditioning and was found to have an optimum. Histological analysis of liver tissue after MSC-CM treatment showed a remarkable reduction in infiltrating leukocytes as well protection of hepatobiliary pathological changes. In addition, we show that MSC-CM actively promotes the emigration of adoptively transferred leukocytes from the injured liver. Finally, we performed a proteomic screen of the MSC secretome and detected high levels of potent chemotactic cytokines. Fractionation of MSC-CM based on affinity to heparin sulfate, a known ligand for all chemokines, revealed that the therapeutic activity of MSC-CM was restricted to the heparin bound fraction, further supporting the role of chemokines as responsible mediators.</p>
</div>

<div id="section2" class="section"><a id="s2" name="s2" toc="s2" title="Results"></a><h3>Results</h3>
<h4>MSC-derived components reverse FHF</h4>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1"></a><p>We first assessed various MSC treatment modalities such as cell transplantation, delivery of cellular lysates or conditioned medium to assess the most efficacious therapy. Sprague-Dawley rats were intraperitoneally administered a total of two injections of 1.2 g/kg of a hepatotoxin, D-galactosamine (Gal-N), each separated by 12 hours <a href="#pone.0000941-Shito1">[14]</a>. With this regimen of liver failure induction, we have previously shown that death occurs 36–72 hours after injection of the first dose and is associated with significant hepatocellular necrosis concomitant with leukocyte infiltration and an increase of inflammatory cytokines in liver tissue. Animals were treated 24 hours after FHF induction with intravenous injections of whole cells or cell lysates. No significant benefit was seen after the intravenous infusion of 2×10<sup>6</sup> human MSCs 24 hours post-induction, which is most likely due to poor engraftment, entrapment in the alveolar capillary bed and/or immune rejection of the cells (<a href="#pone-0000941-g001">Fig. 1</a>). In contrast, treatment with cellular lysates, derived from the same cell mass used for transplantation, showed an increased survival trend compared to vehicle (<em>P</em>&lt;0.47) and fibroblast lysate (<em>P</em>&lt;0.36) controls.</p>
<div class="figure" id="pone-0000941-g001"><div class="img"><a name="pone-0000941-g001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g001.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 1.  <span>Infusion of MSC lysate provides a survival trend in an animal model of FHF.</span></strong></p><a id="article1.body1.sec2.sec1.fig1.caption1.p1" name="article1.body1.sec2.sec1.fig1.caption1.p1"></a><p>Sprague-Dawley rats were administered lethal intraperitoneal injections of a hepatotoxin. Animals were treated with i.v. injections of MSCs, or MSC lysates from the same cell mass (2×10<sup>6</sup> cells). Controls received vehicle or NIH 3T3-J2 fibroblast components. Kaplan-Meier survival analysis of Gal-N administered rats treated with cell transplants or lysates. Time points of interventions are stated above survival plots. Results are cumulative data of two independent experiments (N = 8 per each group) using different batches of MSCs. <em>P</em>-value determined by Log Rank Test.</p>
<span>doi:10.1371/journal.pone.0000941.g001</span></div><a id="article1.body1.sec2.sec1.p2" name="article1.body1.sec2.sec1.p2"></a><p>We then determined if the efficacy observed with lysates could be reproduced by using the secreted molecules from MSCs. A longitudinal study using MSC-CM from the same cell mass (i.e., 2×10<sup>6</sup> human MSCs) revealed a distinct survival benefit compared to vehicle (<em>P</em>&lt;0.032) and fibroblast (<em>P</em>&lt;0.026) concentrated medium (<a href="#pone-0000941-g002">Fig. 2A</a>). In addition, we monitored 72 hour survival of FHF-induced rats as a function of MSC mass from which medium was conditioned (<a href="#pone-0000941-g002">Fig. 2B</a>). Interestingly, the effect of MSC concentrate was abrogated at higher cell masses indicating a therapeutic window of effectiveness. Moreover, the observation that xenogeneic MSC lysates and supernatants decreased animal mortality suggests that these factors can cross species barriers.</p>
<div class="figure" id="pone-0000941-g002"><div class="img"><a name="pone-0000941-g002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g002.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 2.  <span>MSC-CM reverses FHF in a cell mass-dependent manner.</span></strong></p><a id="article1.body1.sec2.sec1.fig2.caption1.p1" name="article1.body1.sec2.sec1.fig2.caption1.p1"></a><p>(A) Kaplan-Meier survival analysis of Gal-N administered rats treated with concentrated MSC-CM. (B) Dose response of animal survival 72 hours after liver failure induction as a function of MSC mass from which MSC-CM was derived. Controls received vehicle or fibroblast conditioned medium (fibroblast-CM). Time points of interventions are stated above survival plots. Results for both panels are cumulative data of two independent experiments using different batches of MSC-CM (N = 8 per each group). <em>P</em>-value determined by Log Rank Test.</p>
<span>doi:10.1371/journal.pone.0000941.g002</span></div>

<h4>Combined metabolic and secretory function in MSC-EB support provide hepatoprotection and survival benefit</h4>
<a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1"></a><p>Based on these results, we then developed a MSC-EB to combine the effectiveness of intracellular and secreted molecules of MSCs in a single device. Animals were treated 24 hours after FHF induction with a human MSC-EB connected to the systemic circulation of the animal. Bioreactors seeded with fibroblasts (fibroblast-EB) and acellular (acellular-EB) bioreactors served as controls. After 10 hours of extracorporeal perfusion, animals were taken off assist support and monitored for survival. Plasma was obtained at the start of, and 24 hours after, bioreactor treatment and analyzed for hepatocyte enzyme release. Liver serologies, including aspartate aminotransferase (<em>P</em>&lt;0.02) and alanine aminotransferase (<em>P</em>&lt;0.001) were improved in animals treated with the MSC-EB (<a href="#pone-0000941-g003">Fig. 3A</a>). These data demonstrate a hepatoprotective effect of device therapy as shown by the reduction in biochemical markers of hepatocyte death. More importantly, 71% of animals treated with the MSC-EB survived, compared to 14% (<a href="#pone-0000941-g003">Fig. 3B</a>) in both acellular (<em>P</em>&lt;0.037) and fibroblast controls (<em>P</em>&lt;0.05).</p>
<div class="figure" id="pone-0000941-g003"><div class="img"><a name="pone-0000941-g003" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g003&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g003"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g003&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g003/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g003/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g003/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g003/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g003.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g003/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g003/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g003.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 3.  <span>MSC-EB support reduces liver injury biomarkers and increases survival.</span></strong></p><a id="article1.body1.sec2.sec2.fig1.caption1.p1" name="article1.body1.sec2.sec2.fig1.caption1.p1"></a><p>Animals were treated with an MSC-EB, using a 3T3 fibroblast-based bioreactor (fibroblast-EB) and an acellular bioreactor (acellular-EB) as controls. (A) Serum biomarkers of liver injury, aspartate aminotransferase and alanine aminotransferase preceding and 24 hours after treatment with a MSC-EB (n = 5) or an acellular-EB (n = 3). Due to mortality, n = 1 in the acellular group after treatment. (B) Kaplan-Meier survival analysis of Gal-N administered rats treated with EBs. Time points of interventions are stated above survival plots. Each result for (B) was an independent experiment using different batches of MSCs. <em>P</em>-value determined by student's t-test analysis for panel (A). <em>P</em>-value determined by Log Rank Test for panel (B).</p>
<span>doi:10.1371/journal.pone.0000941.g003</span></div>

<h4>MSC-CM therapy inhibits panlobular leukocyte invasion, bile duct duplication and hepatocellular death</h4>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1"></a><p>In order to determine histopathological changes after MSC-CM therapy we used a sub-lethal regimen Gal-N to induce acute liver injury, thereby ensuring survival in our control-treated group for comparison. It should be noted that even at this Gal-N dose, mortality occurred in a vehicle-treated group (N = 1) confirming that the extent of injury in this model can still be fatal. Gal-N injured rats were treated with vehicle (N = 4) or MSC-CM (N = 4) 24 hours after injury and their livers were harvested 36 hours thereafter for pathological analysis. Microscopic evaluation of liver tissue from vehicle treated rats revealed profound hepatocellular apoptosis, bile duct duplication and panlobular mononuclear leukocyte infiltration with cytoplasmic vacuolization and severe distortion of tissue architecture (<a href="#pone-0000941-g004">Fig. 4A,C</a>). MSC-CM treated rats showed no signs of disseminated inflammation (<a href="#pone-0000941-g004">Fig. 4B</a>), although minor periportal infiltration with edema and fibrin deposition consistent with tissue repair was observed (<a href="#pone-0000941-g004">Fig. 4D</a>).</p>
<div class="figure" id="pone-0000941-g004"><div class="img"><a name="pone-0000941-g004" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g004&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g004"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g004&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g004/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g004/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g004/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g004/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g004.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g004/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g004/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g004.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 4.  <span>MSC-CM treatment inhibits immune cell infiltration and hepatobiliary cell change in Gal-N injured liver tissue.</span></strong></p><a id="article1.body1.sec2.sec3.fig1.caption1.p1" name="article1.body1.sec2.sec3.fig1.caption1.p1"></a><p>Representative H&amp;E histology sections of liver tissue from Gal-N injured rats 36 hours post-treatment with vehicle (A,C) or MSC-CM (B, D). Scale bars are indicated on the micrographs. Images (A, B) and (C,D) are captured 10× and 20× magnification, respectively.</p>
<span>doi:10.1371/journal.pone.0000941.g004</span></div>

<h4>MSC-CM treatment alters immune cell migration to the liver</h4>
<a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1"></a><p>We hypothesized that one potential explanation for the lack of panlobular leukocyte infiltration may be that MSC-CM treatment may divert immune cell migration away from an inflamed, target organ. To test this theory, we adoptively transferred radiolabeled leukocytes, directly after MSC-CM or vehicle treatment, into Gal-N (0.6 g/kg) injured rats and monitored leukocyte trafficking using single photon emission computed tomography (SPECT) over time (<a href="#pone-0000941-g005">Fig. 5A</a>). Qualitatively, more leukocytes were seen migrating to the liver in vehicle treated animals over time (<a href="#pone-0000941-g005">Fig. 5E–G</a>). In contrast, there was a distinct decrease in signal intensity in the liver of MSC-CM treated animals over time (<a href="#pone-0000941-g005">Fig. 5B–D</a>). These results suggest that there was a selective pressure upon leukocytes to emigrate from the liver due to MSC-CM, unlike control conditions where leukocytes eventually migrated to the injured organ. These data support our hypothesis that altered leukocyte migration may be a potential target of MSC-CM therapy, however other explanations cannot be ruled out without more comprehensive investigations.</p>
<div class="figure" id="pone-0000941-g005"><div class="img"><a name="pone-0000941-g005" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g005&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g005"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g005&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g005/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g005/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g005/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g005/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g005.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g005/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g005/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g005.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 5.  <span>Alteration in leukocyte migration after MSC-CM treatment.</span></strong></p><a id="article1.body1.sec2.sec4.fig1.caption1.p1" name="article1.body1.sec2.sec4.fig1.caption1.p1"></a><p>(A) Experimental design of adoptive transfer study. Gal-N injured rats were treated with vehicle or MSC-CM followed by infusion of In<sup>111</sup>-labeled leukocytes. SPECT images were acquired at t = 0, 3, and 24 hr. for MSC-CM (B–D) and vehicle (E–G) treated rats, respectively.</p>
<span>doi:10.1371/journal.pone.0000941.g005</span></div>

<h4>MSC-CM is composed of many chemokines that correlate with therapeutic activity</h4>
<a id="article1.body1.sec2.sec5.p1" name="article1.body1.sec2.sec5.p1"></a><p>In an effort to understand the molecular mediators of the observed effects of MSC therapy, we examined MSC-CM using a high-density protein array. MSC-CM contained 69 of the 174 proteins assayed (<a href="#pone-0000941-g006">Fig. 6A</a>), which included a broad spectrum of molecules involved in immunomodulation and liver regeneration. Cluster analysis revealed that a large fraction (30%) of MSC-CM was composed of chemokines (<a href="#pone-0000941-g006">Fig. 6B</a>), many of which were expressed at very high relative levels. We decided to fractionate MSC-CM based on functionality using affinity-based methods rather than other arbitrary molecular criteria such as size or hydrophobicity. MSC-CM was passed over an affinity column impregnated with heparin sulfate, a known ligand for all chemokines and separated into bound and unbound fractions. Each fraction was infused into FHF-induced rats with overall survival as the study endpoint. We observed that the therapeutic activity of MSC-CM was restricted to the heparin bound fraction, providing a strong correlation between chemokines and the survival benefit after MSC-CM infusion in FHF-induced rats (<a href="#pone-0000941-g006">Fig. 6C</a>).</p>
<div class="figure" id="pone-0000941-g006"><div class="img"><a name="pone-0000941-g006" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g006&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0000941" data-uri="info:doi/10.1371/journal.pone.0000941.g006"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0000941.g006&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g006/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g006/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g006/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g006/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g006.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0000941.g006/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0000941.g006/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0000941.g006.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 6.  <span>MSC-CM is composed of high levels of chemokines that correlate with survival benefit seen in FHF.</span></strong></p><a id="article1.body1.sec2.sec5.fig1.caption1.p1" name="article1.body1.sec2.sec5.fig1.caption1.p1"></a><p>Serum-free MSC-CM was analyzed using an antibody array for 174 specified proteins. (A) Densiometry of spotted antibody array results. Data are presented as spot intensity relative to the negative control and normalized to positive control. (B) Pie chart showing cluster analysis of MSC secreted proteins based on reported function. MSC-CM was fractionated over a heparin-agarose column into heparin bound and unbound fractions. (C) Kaplan-Meier survival analysis of Gal-N administered rats treated with the (+) heparin MSC-CM and (−) heparin MSC-CM. Time points of interventions are stated above survival plots. Results for (C) are cumulative data of two independent experiments using different batches of MSC-CM (N = 8 per each group). <em>P</em>-value determined by Log Rank Test.</p>
<span>doi:10.1371/journal.pone.0000941.g006</span></div>
</div>

<div id="section3" class="section"><a id="s3" name="s3" toc="s3" title="Discussion"></a><h3>Discussion</h3><a id="article1.body1.sec3.p1" name="article1.body1.sec3.p1"></a><p>Our findings demonstrate that MSC-derived molecules can protect against hepatocyte death and increase survival in Gal-N induced FHF. Specifically, we have shown that an intravenous bolus of MSC-CM during active disease can reverse organ failure. The efficacy of MSC-CM was found to be a function of the cell mass from which media were conditioned suggesting important pharmacological aspects of this treatment. Treatment with a MSC-EB, which combined both the secretory and metabolic functions of MSCs in a single device, provided the greatest benefit in survival and potentially illustrates a platform to study stem cell function and the bone marrow microenvironment <em>ex vivo</em>. These results are significant because we have identified a non-hepatic source of human cells with minimal metabolic demands that can be expanded to clinical scale for liver assist devices and shown that MSC treatment can cross species barriers.</p>
<a id="article1.body1.sec3.p2" name="article1.body1.sec3.p2"></a><p>Histological evaluation of liver tissue after MSC-CM treatment provided initial insight into the cellular targets of therapy. A striking reduction in mononuclear leukocytes was seen post-treatment, suggesting that MSC-CM may inhibit the ability of immune cells to invade and/or function within the injured tissue. Using SPECT imaging of adoptively transferred leukocytes, we provide evidence showing altered immune cell migration after MSC-CM treatment supporting our hypothesis that MSC-CM modulated the immune response to organ injury. Interestingly, it appears that MSC-CM did not divert leukocyte trafficking from the injured site initially, but rather induced a selective emigration of homed leukocytes out of the organ. In addition, we observed prevention of hepatocyte apoptosis and inhibition of bile duct duplication after MSC-CM treatment. Further investigation is needed to determine if these are direct or indirect effects of MSC-CM as well as the temporal sequence of histological changes to evaluate which processes are the primary targets of MSC-CM and which are merely secondary effects.</p>
<a id="article1.body1.sec3.p3" name="article1.body1.sec3.p3"></a><p>Proteomic analysis of MSC-CM revealed a broad spectrum of molecules involved in immunomodulation and liver regeneration. Powered by our knowledge that MSC-CM specifically alters leukocyte migration, we first looked at chemotactic cytokines as potential mediators of the therapeutic effect of MSC-CM. Approximately 30% of MSC-CM was composed of relatively high levels of potent chemokines that, when fractionated based on heparin binding affinity, correlated with the therapeutic activity of MSC-CM. We are currently testing individual chemokines and combinations thereof to demonstrate a casual relationship. Moreover, since any positively charged molecule can ionically interact with heparin sulfate, we cannot rule out other heparin binding compounds such hepatocyte growth factor within the screen of MSC-CM.</p>
<a id="article1.body1.sec3.p4" name="article1.body1.sec3.p4"></a><p>In conclusion, we describe the first use of the secreted and metabolic functions of MSCs to derive a new class of immunotherapeutics. Whether this strategy of MSC-CM or MSC-EB therapy is a relevant means of treatment for other organ failure and inflammatory conditions should be experimentally explored.</p>
</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Materials and Methods"></a><h3>Materials and Methods</h3><a id="article1.body1.sec4.p1" name="article1.body1.sec4.p1"></a><p>Materials were purchased from Sigma-Aldrich, St. Louis, MO unless otherwise stated.</p>

<h4>Cell Culture</h4>
<a id="article1.body1.sec4.sec1.p1" name="article1.body1.sec4.sec1.p1"></a><p>Human MSCs were isolated from commercially available bone marrow aspirates (Clonetics-Poietics, Walkersville, MD) and grown and characterized as previously reported <a href="#pone.0000941-Parekkadan1">[15]</a>. Cells were used for experiments during passages 3-7. NIH 3T3-J2 fibroblasts were a kind gift from Dr. Howard Green and cultured according to donor's protocols.</p>


<h4>Preparation and delivery of cells, cell lysates and conditioned medium</h4>
<a id="article1.body1.sec4.sec2.p1" name="article1.body1.sec4.sec2.p1"></a><p>Cellular lysates were prepared by sonication (VWR Scientific, West Chester, PA). The dose of sonicated cells administered was 2×10<sup>6</sup> cells per subject, which represented the same cell mass used for extracorporeal bioreactor or cell transplant experiments. Conditioned medium was prepared by collecting serum-free medium (supplemented with 0.05% bovine serum albumin to prevent protein aggregation) after 24 hour culture of different cell masses. The majority of experiments were performed with the optimal cell mass of 2×10<sup>6</sup> cells. The medium was then concentrated, approximately 25 fold, using ultrafiltration units (Amicon Ultra-PL 3, Millipore, Bedford, MA, USA) with a 3 kDa molecular weight cut-off. For fractionation experiments, concentrated medium was passed over a heparin-agarose column and the flow-through and eluted fractions were collected and reconcentrated using the same ultrafiltration system. A total volume of 500 µl containing cells, cellular lysates, vehicle (PBS) only or 900 µl of conditioned medium was infused in the penile vein 24 hours after induction of FHF using the same anaesthesia protocol described for the cannulation procedure.</p>


<h4>Liver Failure Induction and Extracorporeal Bioreactor Support</h4>
<a id="article1.body1.sec4.sec3.p1" name="article1.body1.sec4.sec3.p1"></a><p>The induction of fulminant hepatic failure and extracorporeal device operation is previously reported <a href="#pone.0000941-Shinoda1">[2]</a>. Briefly, male Sprague-Dawley rats weighing between 280 and 370 grams were anaesthetized using intraperitoneal injections of ketamine and xylazine at 110 and 0.4 mg/kg, respectively. The left carotid artery and right jugular vein were cannulated and the animal was placed in a metabolic cage. Twenty-four hours later, 1.2 g/kg Gal-N freshly dissolved in physiological saline and adjusted to pH 7.3 with 1 N NaOH was injected i.p., followed by a second equal injection 12 hours later. Twenty-four hours after the first injection of Gal-N, the arterial and venous lines were connected to an extracorporeal circuit. Plasma was separated using a plasma separator (MicroKros, pore size 0.2 micron). Plasma was perfused through the polycarbonate, flat-plate bioreactor and subsequently reunited with the cellular components of the blood and returned to the animal. The extracorporeal bioreactor was operated for 10 hours. Animals that died during reactor operation and failed to receive adequate treatment (MSC-EB, N = 3 and Fibroblast-EB, N = 2) were censored from analysis. Animal survival was monitored every 12 hours. Plasma or whole blood was analyzed for liver injury biomarkers using a microfluidic metabolic assay (Picollo, Abaxis, Union City, CA).</p>


<h4>Liver Histology</h4>
<a id="article1.body1.sec4.sec4.p1" name="article1.body1.sec4.sec4.p1"></a><p>Liver tissue was harvested from rats induced with a sub-lethal regimen of Gal-N (0.6 g/kg), 36 hours after treatment with MSC-CM. Tissue was fixed in 10% buffered formalin, embedded in paraffin, sectioned to 6-µm thickness, and stained with hematoylin and eosin.</p>


<h4>Adoptive transfer of radiolabeled leukocytes</h4>
<a id="article1.body1.sec4.sec5.p1" name="article1.body1.sec4.sec5.p1"></a><p>Leukocytes were isolated from whole rat blood by NH<sub>4</sub>Cl erythrocyte lysis. Cells were pelleted, washed once with PBS and resuspended in 0.9% saline containing the In<sup>111</sup> oxine isotope (GE Healthcare Biosciences Corp., Piscataway, NJ). Cells were labeled at 92% efficiency with high viability. Approximately 15×10<sup>6</sup> cells were infused into the penile vein of Gal-N injured (0.6 g/kg) directly after treatment with vehicle or MSC-CM. SPECT images were captured using a M.CAM gamma camera setup (Siemens Medical Systems, Malvern, PA) at 0, 3 and 24 hours after leukocyte infusion.</p>


<h4>Protein array of MSC supernatants</h4>
<a id="article1.body1.sec4.sec6.p1" name="article1.body1.sec4.sec6.p1"></a><p>Supernatants were prepared by collecting serum-free medium after 24 hour culture of approximately 2×10<sup>6</sup> MSCs. These were analyzed for a panel of specified proteins using an antibody array (RayBio Human Cytokine Antibody Array C Series 2000, RayBiotech Inc., Norcross, GA) as specified by the vendor.</p>

</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>We thank Drs. Zaki Megeed, Richard N. Mitchell and Yaakov Nahmias for critique of the work and Donald Poulsen for illustrations and figure preparation. We also thank Robert Crowther for histological preparations.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: BP Dv FB AT MY. Performed the experiments: BP Dv KS EC. Analyzed the data: BP Dv KS. Contributed reagents/materials/analysis tools: EC. Wrote the paper: BP MY.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0000941-Strain1" id="pone.0000941-Strain1"></a>Strain AJ, Neuberger JM (2002) A bioartificial liver–state of the art. Science  295: 1005–1009.  <ul class="find" data-citedArticleID="996504" data-doi="10.1126/science.1068660"><li><a href="http://dx.doi.org/10.1126/science.1068660" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+bioartificial+liver%E2%80%93state+of+the+art." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+bioartificial+liver%E2%80%93state+of+the+art.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">2.
              </span><a name="pone.0000941-Shinoda1" id="pone.0000941-Shinoda1"></a>Shinoda M, Tilles AW, Kobayashi N, Wakabayashi G, Takayanagi A, et al.  (2007) A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats. J Surg Res  137: 130–140.  <ul class="find" data-citedArticleID="996498" data-doi="10.1016/j.jss.2006.08.009"><li><a href="http://dx.doi.org/10.1016/j.jss.2006.08.009" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+bioartificial+liver+device+secreting+interleukin-1+receptor+antagonist+for+the+treatment+of+hepatic+failure+in+rats." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+bioartificial+liver+device+secreting+interleukin-1+receptor+antagonist+for+the+treatment+of+hepatic+failure+in+rats.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">3.
              </span><a name="pone.0000941-Shinoda2" id="pone.0000941-Shinoda2"></a>Shinoda M, Tilles AW, Wakabayashi G, Takayanagi A, Harada H, et al.  (2006) Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist. Tissue Eng  12: 1313–1323.  <ul class="find" data-citedArticleID="996500" data-doi="10.1089/ten.2006.12.1313"><li><a href="http://dx.doi.org/10.1089/ten.2006.12.1313" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Treatment+of+fulminant+hepatic+failure+in+rats+using+a+bioartificial+liver+device+containing+porcine+hepatocytes+producing+interleukin-1+receptor+antagonist." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Treatment+of+fulminant+hepatic+failure+in+rats+using+a+bioartificial+liver+device+containing+porcine+hepatocytes+producing+interleukin-1+receptor+antagonist.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">4.
              </span><a name="pone.0000941-Dazzi1" id="pone.0000941-Dazzi1"></a>Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I (2006) The role of mesenchymal stem cells in haemopoiesis. Blood Rev  20: 161–171.  <ul class="find" data-citedArticleID="996482" data-doi="10.1016/j.blre.2005.11.002"><li><a href="http://dx.doi.org/10.1016/j.blre.2005.11.002" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+role+of+mesenchymal+stem+cells+in+haemopoiesis." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+role+of+mesenchymal+stem+cells+in+haemopoiesis.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">5.
              </span><a name="pone.0000941-Liechty1" id="pone.0000941-Liechty1"></a>Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, et al.  (2000) Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med  6: 1282–1286.  <ul class="find" data-citedArticleID="996490"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Human+mesenchymal+stem+cells+engraft+and+demonstrate+site-specific+differentiation+after+in+utero+transplantation+in+sheep.&amp;auth=&amp;atitle=Human+mesenchymal+stem+cells+engraft+and+demonstrate+site-specific+differentiation+after+in+utero+transplantation+in+sheep." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Human+mesenchymal+stem+cells+engraft+and+demonstrate+site-specific+differentiation+after+in+utero+transplantation+in+sheep." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Human+mesenchymal+stem+cells+engraft+and+demonstrate+site-specific+differentiation+after+in+utero+transplantation+in+sheep.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">6.
              </span><a name="pone.0000941-LeBlanc1" id="pone.0000941-LeBlanc1"></a>Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, et al.  (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet  363: 1439–1441.  <ul class="find" data-citedArticleID="996488" data-doi="10.1016/s0140-6736(04)16104-7"><li><a href="http://dx.doi.org/10.1016/s0140-6736(04)16104-7" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Treatment+of+severe+acute+graft-versus-host+disease+with+third+party+haploidentical+mesenchymal+stem+cells." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Treatment+of+severe+acute+graft-versus-host+disease+with+third+party+haploidentical+mesenchymal+stem+cells.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0000941-Aggarwal1" id="pone.0000941-Aggarwal1"></a>Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood  105: 1815–1822.  <ul class="find" data-citedArticleID="996478" data-doi="10.1182/blood-2004-04-1559"><li><a href="http://dx.doi.org/10.1182/blood-2004-04-1559" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Human+mesenchymal+stem+cells+modulate+allogeneic+immune+cell+responses." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Human+mesenchymal+stem+cells+modulate+allogeneic+immune+cell+responses.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">8.
              </span><a name="pone.0000941-Zhang1" id="pone.0000941-Zhang1"></a>Zhang Y, Adachi Y, Suzuki Y, Minamino K, Iwasaki M, et al.  (2004) Simultaneous injection of bone marrow cells and stromal cells into bone marrow accelerates hematopoiesis in vivo. Stem Cells  22: 1256–1262.  <ul class="find" data-citedArticleID="996506" data-doi="10.1634/stemcells.2004-0173"><li><a href="http://dx.doi.org/10.1634/stemcells.2004-0173" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Simultaneous+injection+of+bone+marrow+cells+and+stromal+cells+into+bone+marrow+accelerates+hematopoiesis+in+vivo." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Simultaneous+injection+of+bone+marrow+cells+and+stromal+cells+into+bone+marrow+accelerates+hematopoiesis+in+vivo.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">9.
              </span><a name="pone.0000941-Meisel1" id="pone.0000941-Meisel1"></a>Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, et al.  (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood  103: 4619–4621.  <ul class="find" data-citedArticleID="996494" data-doi="10.1182/blood-2003-11-3909"><li><a href="http://dx.doi.org/10.1182/blood-2003-11-3909" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Human+bone+marrow+stromal+cells+inhibit+allogeneic+T-cell+responses+by+indoleamine+2%2C3-dioxygenase-mediated+tryptophan+degradation." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Human+bone+marrow+stromal+cells+inhibit+allogeneic+T-cell+responses+by+indoleamine+2%2C3-dioxygenase-mediated+tryptophan+degradation.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">10.
              </span><a name="pone.0000941-Beyth1" id="pone.0000941-Beyth1"></a>Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, et al.  (2005) Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood  105: 2214–2219.  <ul class="find" data-citedArticleID="996480" data-doi="10.1182/blood-2004-07-2921"><li><a href="http://dx.doi.org/10.1182/blood-2004-07-2921" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Human+mesenchymal+stem+cells+alter+antigen-presenting+cell+maturation+and+induce+T-cell+unresponsiveness." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Human+mesenchymal+stem+cells+alter+antigen-presenting+cell+maturation+and+induce+T-cell+unresponsiveness.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">11.
              </span><a name="pone.0000941-Maitra1" id="pone.0000941-Maitra1"></a>Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, et al.  (2004) Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant  33: 597–604.  <ul class="find" data-citedArticleID="996492" data-doi="10.1038/sj.bmt.1704400"><li><a href="http://dx.doi.org/10.1038/sj.bmt.1704400" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Human+mesenchymal+stem+cells+support+unrelated+donor+hematopoietic+stem+cells+and+suppress+T-cell+activation." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Human+mesenchymal+stem+cells+support+unrelated+donor+hematopoietic+stem+cells+and+suppress+T-cell+activation.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">12.
              </span><a name="pone.0000941-Gnecchi1" id="pone.0000941-Gnecchi1"></a>Gnecchi M, He H, Liang OD, Melo LG, Morello F, et al.  (2005) Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med  11: 367–368.  <ul class="find" data-citedArticleID="996484" data-doi="10.1038/nm0405-367"><li><a href="http://dx.doi.org/10.1038/nm0405-367" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Paracrine+action+accounts+for+marked+protection+of+ischemic+heart+by+Akt-modified+mesenchymal+stem+cells." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Paracrine+action+accounts+for+marked+protection+of+ischemic+heart+by+Akt-modified+mesenchymal+stem+cells.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">13.
              </span><a name="pone.0000941-Gnecchi2" id="pone.0000941-Gnecchi2"></a>Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, et al.  (2006) Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. Faseb J  20: 661–669.  <ul class="find" data-citedArticleID="996486" data-doi="10.1096/fj.05-5211com"><li><a href="http://dx.doi.org/10.1096/fj.05-5211com" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Evidence+supporting+paracrine+hypothesis+for+Akt-modified+mesenchymal+stem+cell-mediated+cardiac+protection+and+functional+improvement." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Evidence+supporting+paracrine+hypothesis+for+Akt-modified+mesenchymal+stem+cell-mediated+cardiac+protection+and+functional+improvement.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">14.
              </span><a name="pone.0000941-Shito1" id="pone.0000941-Shito1"></a>Shito M, Balis UJ, Tompkins RG, Yarmush ML, Toner M (2001) A fulminant hepatic failure model in the rat: involvement of interleukin-1beta and tumor necrosis factor-alpha. Dig Dis Sci  46: 1700–1708.  <ul class="find" data-citedArticleID="996502"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=A+fulminant+hepatic+failure+model+in+the+rat%3A+involvement+of+interleukin-1beta+and+tumor+necrosis+factor-alpha.&amp;auth=&amp;atitle=A+fulminant+hepatic+failure+model+in+the+rat%3A+involvement+of+interleukin-1beta+and+tumor+necrosis+factor-alpha." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+fulminant+hepatic+failure+model+in+the+rat%3A+involvement+of+interleukin-1beta+and+tumor+necrosis+factor-alpha." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+fulminant+hepatic+failure+model+in+the+rat%3A+involvement+of+interleukin-1beta+and+tumor+necrosis+factor-alpha.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">15.
              </span><a name="pone.0000941-Parekkadan1" id="pone.0000941-Parekkadan1"></a>Parekkadan B, van Poll D, Megeed Z, Tilles AW, Berthiaume F, et al.  (2007) Immunomodulation of Activated Hepatic Stellate Cells by Mesenchymal Stem Cells. Biochem Biophys Res Commun..   in press.  <ul class="find" data-citedArticleID="996496" data-doi="10.1016/j.bbrc.2007.05.150"><li><a href="http://dx.doi.org/10.1016/j.bbrc.2007.05.150" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Immunomodulation+of+Activated+Hepatic+Stellate+Cells+by+Mesenchymal+Stem+Cells." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Immunomodulation+of+Activated+Hepatic+Stellate+Cells+by+Mesenchymal+Stem+Cells.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.XML" value="48335"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.PDF" value="358380"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g001.PNG_L" value="20356"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g001.PNG_M" value="34391"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g001.PNG_S" value="7748"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g001.TIF" value="32586"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g001.PNG_I" value="12366"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g002.PNG_L" value="103639"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g002.PNG_M" value="23675"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g002.PNG_S" value="5516"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g002.TIF" value="210116"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g002.PNG_I" value="8707"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g003.PNG_L" value="149710"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g003.PNG_M" value="34220"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g003.PNG_S" value="8736"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g003.TIF" value="304816"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g003.PNG_I" value="24770"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g004.PNG_L" value="8688190"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g004.PNG_M" value="691323"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g004.PNG_S" value="17882"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g004.TIF" value="12145386"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g004.PNG_I" value="202506"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g005.PNG_L" value="1922070"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g005.PNG_M" value="238686"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g005.PNG_S" value="9507"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g005.TIF" value="2492446"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g005.PNG_I" value="70744"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g006.PNG_L" value="530426"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g006.PNG_M" value="66515"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g006.PNG_S" value="9304"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g006.TIF" value="589494"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0000941.g006.PNG_I" value="23967"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000941&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0000941" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0000941&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0000941&volume=&issue=&title=Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure&author_name=Biju%20Parekkadan%2C%20Daan%20van%20Poll%2C%20Kazuhiro%20Suganuma%2C%20Edward%20A.%20Carter%2C%20Fran%C3%A7ois%20Berthiaume%2C%20Arno%20W.%20Tilles%2C%20Martin%20L.%20Yarmush&start_page=1&end_page=6" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000941" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000941" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0000941" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000941&amp;t=Mesenchymal%20Stem%20Cell-Derived%20Molecules%20Reverse%20Fulminant%20Hepatic%20Failure" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000941&title=Mesenchymal%20Stem%20Cell-Derived%20Molecules%20Reverse%20Fulminant%20Hepatic%20Failure&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000941&amp;title=Mesenchymal%20Stem%20Cell-Derived%20Molecules%20Reverse%20Fulminant%20Hepatic%20Failure" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000941" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0000941&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0000941';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20Mesenchymal%20Stem%20Cell-Derived%20Molecules%20Reverse%20Fulminant%20Hepatic%20Failure http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0000941" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0000941" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">


















          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Biological+tissue%22" title="Search for articles in the subject area:'Biological tissue'"><div class="flagText">Biological tissue</div></a>
              <div data-categoryid="48061" data-articleid="24720"
                   data-categoryname="Biological tissue"
                   class="flagImage" title="Flag 'Biological tissue' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Chemokines%22" title="Search for articles in the subject area:'Chemokines'"><div class="flagText">Chemokines</div></a>
              <div data-categoryid="19547" data-articleid="24720"
                   data-categoryname="Chemokines"
                   class="flagImage" title="Flag 'Chemokines' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Fibroblasts%22" title="Search for articles in the subject area:'Fibroblasts'"><div class="flagText">Fibroblasts</div></a>
              <div data-categoryid="47975" data-articleid="24720"
                   data-categoryname="Fibroblasts"
                   class="flagImage" title="Flag 'Fibroblasts' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Heparin%22" title="Search for articles in the subject area:'Heparin'"><div class="flagText">Heparin</div></a>
              <div data-categoryid="22599" data-articleid="24720"
                   data-categoryname="Heparin"
                   class="flagImage" title="Flag 'Heparin' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Hepatocytes%22" title="Search for articles in the subject area:'Hepatocytes'"><div class="flagText">Hepatocytes</div></a>
              <div data-categoryid="47449" data-articleid="24720"
                   data-categoryname="Hepatocytes"
                   class="flagImage" title="Flag 'Hepatocytes' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Immune+cells%22" title="Search for articles in the subject area:'Immune cells'"><div class="flagText">Immune cells</div></a>
              <div data-categoryid="33873" data-articleid="24720"
                   data-categoryname="Immune cells"
                   class="flagImage" title="Flag 'Immune cells' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Mesenchymal+stem+cells%22" title="Search for articles in the subject area:'Mesenchymal stem cells'"><div class="flagText">Mesenchymal stem cells</div></a>
              <div data-categoryid="21505" data-articleid="24720"
                   data-categoryname="Mesenchymal stem cells"
                   class="flagImage" title="Flag 'Mesenchymal stem cells' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22White+blood+cells%22" title="Search for articles in the subject area:'White blood cells'"><div class="flagText">White blood cells</div></a>
              <div data-categoryid="18601" data-articleid="24720"
                   data-categoryname="White blood cells"
                   class="flagImage" title="Flag 'White blood cells' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=3404'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=6502'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=7813&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>

<div class="block sidebar-comments">
    <div class="header">
        <h3>Comments</h3>
    </div>
      <p><a href="/annotation/listThread.action?root=10071">Do you have data on this? </a><br>Posted by StemCellGeek</p>
      <p><a href="/annotation/listThread.action?root=18145">Referee Comments: Referee 2</a><br>Posted by PLoS_ONE_Group</p>
</div>

</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
